Computer-guided design of optimal microbial consortia for immune system modulation

  1. Richard R Stein  Is a corresponding author
  2. Takeshi Tanoue
  3. Rose L Szabady
  4. Shakti K Bhattarai
  5. Bernat Olle
  6. Jason M Norman
  7. Wataru Suda
  8. Kenshiro Oshima
  9. Masahira Hattori
  10. Georg K Gerber
  11. Chris Sander
  12. Kenya Honda
  13. Vanni Bucci  Is a corresponding author
  1. Dana-Farber Cancer Institute, United States
  2. RIKEN Institute, Japan
  3. Vedanta Biosciences, Inc, United States
  4. University of Massachusetts, United States
  5. Keio University School of Medicine, Japan
  6. The University of Tokyo, Japan
  7. Brigham and Women's Hospital, United States

Abstract

Manipulation of the gut microbiota holds great promise for the treatment of diseases. However, a major challenge is the identification of therapeutically potent microbial consortia that colonize the host effectively while maximizing immunologic outcome. Here, we propose a novel workflow to select optimal immune-inducing consortia from microbiome composition and immune effectors measurements. Using published and newly generated microbial and regulatory T-cell (Treg) data from germ-free mice, we estimate the contribution of twelve Clostridia strains with known immune-modulating effect to Treg induction. Combining this with a longitudinal data-constrained ecological model, we predict the ability of every attainable and ecologically stable subconsortium in promoting Treg activation and rank them by the Treg Induction Score (TrIS). Experimental validation of selected consortia indicates a strong and statistically significant correlation between predicted TrIS and measured Treg. We argue that computational indexes, such as the TrIS, are valuable tools for the systematic selection of immune-modulating bacteriotherapeutics.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Richard R Stein

    Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, United States
    For correspondence
    stein@jimmy.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5110-6863
  2. Takeshi Tanoue

    Center for Integrative Medical Sciences, RIKEN Institute, Yokohama City, Japan
    Competing interests
    Takeshi Tanoue, Has received support from Vedanta Biosciences, Inc. under research agreement with his institution.
  3. Rose L Szabady

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Rose L Szabady, Is employee of Vedanta Biosciences, Inc.
  4. Shakti K Bhattarai

    Engineering and Applied Sciences PhD Program, University of Massachusetts, Dartmouth, United States
    Competing interests
    No competing interests declared.
  5. Bernat Olle

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Bernat Olle, Is the Chief Executive Officer of Vedanta Biosciences, Inc.
  6. Jason M Norman

    Vedanta Biosciences, Inc, Cambridge, United States
    Competing interests
    Jason M Norman, Is employee of Vedanta Biosciences, Inc.
  7. Wataru Suda

    Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  8. Kenshiro Oshima

    Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
    Competing interests
    No competing interests declared.
  9. Masahira Hattori

    Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
    Competing interests
    No competing interests declared.
  10. Georg K Gerber

    Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    Georg K Gerber, Is a member of the Scientific Advisory Board of Kaleido, Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9149-5509
  11. Chris Sander

    Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  12. Kenya Honda

    Center for Integrative Medical Sciences, RIKEN Institute, Yokohama City, Japan
    Competing interests
    Kenya Honda, Is a Co-Founder and Scientific Advisory Board Member of Vedanta Biosciences, Inc. Has received support from Vedanta Biosciences, Inc. under research agreements with his institution.
  13. Vanni Bucci

    Engineering and Applied Sciences PhD Program, University of Massachusetts, Dartmouth, United States
    For correspondence
    vanni.bucci@umassd.edu
    Competing interests
    Vanni Bucci, Has received support from Vedanta Biosciences, Inc. under research agreement with his institution.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3257-2922

Funding

National Institutes of Health (P41 GM103504)

  • Richard R Stein
  • Chris Sander

Brigham and Women's Hospital (Precision Medicine Initiative)

  • Georg K Gerber

Defense Advanced Research Projects Agency (BRICS award HR0011-15-C-0094)

  • Georg K Gerber

Human Frontier Science Program (RGP00055/2015)

  • Chris Sander

Takeda Science Foundation

  • Kenya Honda

National Institute of General Medical Sciences (5R01 GM106303)

  • Chris Sander

Japan Agency for Medical Research and Development

  • Kenya Honda

National Institute of Allergy and Infectious Diseases

  • Vanni Bucci

National Science Foundation

  • Vanni Bucci

Core Research for Evolutional Science and Technology

  • Kenya Honda

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: 11-strain time-series mouse experiments were performed under ethical approval by RIKEN, Keio and Azabu Universities under protocol H24-9(14) (RIKEN). 4-strain validation mouse work was performed at Brigham and Women's Hospital in Boston, MA in the Massachusetts Host Microbiome Center under IACUC protocol 2016N000141.

Copyright

© 2018, Stein et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,969
    views
  • 1,369
    downloads
  • 69
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Richard R Stein
  2. Takeshi Tanoue
  3. Rose L Szabady
  4. Shakti K Bhattarai
  5. Bernat Olle
  6. Jason M Norman
  7. Wataru Suda
  8. Kenshiro Oshima
  9. Masahira Hattori
  10. Georg K Gerber
  11. Chris Sander
  12. Kenya Honda
  13. Vanni Bucci
(2018)
Computer-guided design of optimal microbial consortia for immune system modulation
eLife 7:e30916.
https://doi.org/10.7554/eLife.30916

Share this article

https://doi.org/10.7554/eLife.30916

Further reading

    1. Computational and Systems Biology
    Nobuhisa Umeki, Yoshiyuki Kabashima, Yasushi Sako
    Research Article

    The RAS-MAPK system plays an important role in regulating various cellular processes, including growth, differentiation, apoptosis, and transformation. Dysregulation of this system has been implicated in genetic diseases and cancers affecting diverse tissues. To better understand the regulation of this system, we employed information flow analysis based on transfer entropy (TE) between the activation dynamics of two key elements in cells stimulated with EGF: SOS, a guanine nucleotide exchanger for the small GTPase RAS, and RAF, a RAS effector serine/threonine kinase. TE analysis allows for model-free assessment of the timing, direction, and strength of the information flow regulating the system response. We detected significant amounts of TE in both directions between SOS and RAF, indicating feedback regulation. Importantly, the amount of TE did not simply follow the input dose or the intensity of the causal reaction, demonstrating the uniqueness of TE. TE analysis proposed regulatory networks containing multiple tracks and feedback loops and revealed temporal switching in the reaction pathway primarily responsible for reaction control. This proposal was confirmed by the effects of an MEK inhibitor on TE. Furthermore, TE analysis identified the functional disorder of a SOS mutation associated with Noonan syndrome, a human genetic disease, of which the pathogenic mechanism has not been precisely known yet. TE assessment holds significant promise as a model-free analysis method of reaction networks in molecular pharmacology and pathology.

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Eric V Strobl, Eric Gamazon
    Research Article

    Root causal gene expression levels – or root causal genes for short – correspond to the initial changes to gene expression that generate patient symptoms as a downstream effect. Identifying root causal genes is critical towards developing treatments that modify disease near its onset, but no existing algorithms attempt to identify root causal genes from data. RNA-sequencing (RNA-seq) data introduces challenges such as measurement error, high dimensionality and non-linearity that compromise accurate estimation of root causal effects even with state-of-the-art approaches. We therefore instead leverage Perturb-seq, or high-throughput perturbations with single-cell RNA-seq readout, to learn the causal order between the genes. We then transfer the causal order to bulk RNA-seq and identify root causal genes specific to a given patient for the first time using a novel statistic. Experiments demonstrate large improvements in performance. Applications to macular degeneration and multiple sclerosis also reveal root causal genes that lie on known pathogenic pathways, delineate patient subgroups and implicate a newly defined omnigenic root causal model.